Back to search results

Imaging Test for Head and Neck Cancer Spread

This study is looking at a new imaging test called Zirconium Zr 89 Panitumumab (89Zr panitumumab) with PET/CT scans. The goal is to see how well this test can find if head and neck squamous cell carcinoma has spread to other parts of the body (metastasis). Traditional PET/CT scans sometimes have trouble confirming if a spot is truly cancer that has spread. 89Zr panitumumab is a special imaging agent that targets a protein called EGFR, which is often found in head and neck cancers. We want to see if this new test is better at finding these metastatic spots. You may be able to join if you are at least 19 years old and have a confirmed diagnosis of head and neck squamous cell carcinoma, especially if doctors are unsure if your cancer has spread based on previous scans. The study aims to enroll 60 participants, and its current status is unclear.

Study design
This is an interventional study, meaning participants will receive specific treatments or procedures. It plans to enroll 60 participants.
What's involved
Participants will receive Panitumumab and Zirconium Zr 89 Panitumumab intravenously (into a vein). They will also undergo PET/CT scans.
Compensation
Not stated in the trial record.
Follow-up
The study will track how well the imaging test works for up to 7 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05747625

(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma

Recruiting
PHASE1Ages 19+InterventionalSupportive care
Eben Rosenthal
~60 participants
Updated 2026-05-08 on ClinicalTrials.gov
What's tested:PanitumumabZirconium Zr 89 PanitumumabPositron Emission TomographyComputed TomographyElectronic Health Record Review

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Sensitivity of zirconium Zr 89 panitumumab (89Zr-panitumumab
Measured over Up to 7 years
+1 more outcome measured

Conditions

Head and Neck Squamous Cell Carcinoma
Metastatic Head and Neck Squamous Cell Carcinoma
Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck

Explore related trials

Head and Neck Cutaneous Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaSoluble Epidermal Growth Factor Receptor

Where it's being run

1 sites across 1 states
Tennessee1

Study leadership

  • Michael Topf, MD · PRINCIPAL_INVESTIGATOR · Vanderbilt University/Ingram Cancer Center

Who to contact

Nicole Jones
[email protected]
615-936-2807
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age \>= 19 years
Biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck
Subjects diagnosed with any T stage, any subsite within the head and neck. Subjects with recurrent disease or a new primary will be allowed
Must have evidence of indeterminate metastatic squamous cell carcinoma (SCC) based on 18F-fluorodeoxyglucose (FDG)-PET/CT or Primary SCC with suspicious Lymph Nodes on CT prior to surgical removal
Hemoglobin \>= 9gm/dL
White blood cell count \> 3000/mm\^3
Platelet count \>= 100,000/mm\^3
Serum creatinine =\< 1.5 times upper reference range

Exclusion

Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment
History of infusion reactions to other monoclonal antibody therapies
Pregnant (based on screening serum pregnancy test and day 0 urine pregnancy test administered before unlabeled panitumumab), or breastfeeding
Magnesium or potassium lower than the normal institutional values
Subjects receiving class IA (quinidine, procainamide) or class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents
Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis
Severe renal disease or anuria
Known hypersensitivity to deferoxamine or any of its components

What this trial measures

  • Sensitivity of zirconium Zr 89 panitumumab (89Zr-panitumumabUp to 7 years

    The total number of head and neck squamous cell carcinoma lesions accurately detected by 89Zr-panitumumab using positron emission tomography (PET)/computed tomography (CT) imaging (test) will be compared with lesions identified as positive during the 36 +/- 6 month follow-up period (gold standard). Significance will be assessed at an alpha level of 0.05 and, to assess uncertainty, 95% confidence intervals will be provided for all estimates.

  • Specificity of 89Zr-panitumumabUp to 7 years

    The total number of head and neck squamous cell carcinoma lesions accurately detected by 89Zr-panitumumab using PET/CT imaging (test) will be compared with lesions identified as positive during the 36 +/- 6 month follow-up period (gold standard). Significance will be assessed at an alpha level of 0.05 and, to assess uncertainty, 95% confidence intervals will be provided for all estimates.